These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38831641)

  • 1. Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real-world study based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Zhao ZX; Yang TY; Wang YH; Zhang L; Li J; Su YW
    Br J Clin Pharmacol; 2024 Sep; 90(9):2166-2179. PubMed ID: 38831641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy.
    Xiang S; Shen R; Xiang J; Zhu N; Gu J; Shen J; Zhang Y; Ge H
    Expert Opin Drug Saf; 2024 May; 23(5):627-636. PubMed ID: 38456691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world safety profile of zanubrutinib: a disproportionality analysis based on the FAERS database.
    Wang J; Zheng X; Lin J; Huang J; Zhang M; Huang P; Yang X
    BMJ Open; 2024 Oct; 14(10):e084991. PubMed ID: 39419623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
    Sestier M; Hillis C; Fraser G; Leong D
    Curr Oncol Rep; 2021 Aug; 23(10):113. PubMed ID: 34342738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors.
    Zhai Y; Hu F; Shi W; Ye X; Xu J; Guo X; Cao Y; He J; Xu F
    Expert Opin Drug Saf; 2023; 22(9):857-869. PubMed ID: 37070462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
    Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
    Thompson MC; Mato AR
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing toxicities of Bruton tyrosine kinase inhibitors.
    Lipsky A; Lamanna N
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):336-345. PubMed ID: 33275698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Bruton's Tyrosine Kinase in CLL.
    Ahn IE; Brown JR
    Front Immunol; 2021; 12():687458. PubMed ID: 34248972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia.
    Hatashima A; Shadman M
    Expert Rev Hematol; 2024 Oct; 17(10):687-703. PubMed ID: 39163531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
    Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
    Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Toxicities Associated With Ibrutinib.
    Salem JE; Manouchehri A; Bretagne M; Lebrun-Vignes B; Groarke JD; Johnson DB; Yang T; Reddy NM; Funck-Brentano C; Brown JR; Roden DM; Moslehi JJ
    J Am Coll Cardiol; 2019 Oct; 74(13):1667-1678. PubMed ID: 31558250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
    Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
    Moslehi JJ; Furman RR; Tam CS; Salem JE; Flowers CR; Cohen A; Zhang M; Zhang J; Chen L; Ma H; Brown JR
    Blood Adv; 2024 May; 8(10):2478-2490. PubMed ID: 38502198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.
    Awan FT; Addison D; Alfraih F; Baratta SJ; Campos RN; Cugliari MS; Goh YT; Ionin VA; Mundnich S; Sverdlov AL; Tam C; Ysebaert L
    Blood Adv; 2022 Sep; 6(18):5516-5525. PubMed ID: 35790105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Wolska-Washer A; Robak P; Witkowska M; Robak T
    Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):207-224. PubMed ID: 38516702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
    Palma M; Mulder TA; Österborg A
    Front Immunol; 2021; 12():686768. PubMed ID: 34276674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
    Fancher KM; Pappacena JJ
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):507-515. PubMed ID: 32940733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton's Tyrosine Kinase Inhibitor Acalabrutinib.
    Zhao Y; Chakraborty P; Tomassetti J; Subha T; Massé S; Thavendiranathan P; Billia F; Lai PFH; Abdel-Qadir H; Nanthakumar K
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors.
    Aghel N; Baro Vila RC; Lui M; Hillis C; Leong DP
    Curr Cardiol Rep; 2023 Sep; 25(9):941-958. PubMed ID: 37498449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.